Design Therapeutics IncNASDAQ:DSGN
- LAST PRICE5.6200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.5700/ 1
- Ask / Lots6.0000/ 2
- Open / Previous Close5.7100 / 5.6200
- Day Range
- 52 Week Range
- Volume77,441
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DSGN |
|---|---|---|
| 09:32 ET | 549 | 5.71 |
| 09:35 ET | 313 | 5.73 |
| 09:37 ET | 1100 | 5.8 |
| 09:39 ET | 200 | 5.79 |
| 09:42 ET | 342 | 5.89 |
| 09:44 ET | 200 | 5.8 |
| 09:46 ET | 1562 | 5.74 |
| 09:48 ET | 100 | 5.79 |
| 09:50 ET | 1251 | 5.74 |
| 09:51 ET | 100 | 5.78 |
| 09:53 ET | 300 | 5.78 |
| 10:00 ET | 1951 | 5.7237 |
| 10:02 ET | 320 | 5.66 |
| 10:11 ET | 300 | 5.66 |
| 10:13 ET | 100 | 5.64 |
| 10:20 ET | 100 | 5.68 |
| 10:29 ET | 200 | 5.735 |
| 10:36 ET | 1499 | 5.79 |
| 10:44 ET | 267 | 5.7651 |
| 10:47 ET | 2041 | 5.82 |
| 10:54 ET | 100 | 5.83 |
| 10:56 ET | 430 | 5.845 |
| 11:00 ET | 700 | 5.81 |
| 11:12 ET | 1000 | 5.78 |
| 11:27 ET | 410 | 5.79 |
| 11:30 ET | 132 | 5.76 |
| 11:32 ET | 200 | 5.8 |
| 11:36 ET | 100 | 5.805 |
| 11:39 ET | 400 | 5.73 |
| 12:14 ET | 1533 | 5.73 |
| 12:15 ET | 519 | 5.7 |
| 12:17 ET | 100 | 5.69 |
| 12:21 ET | 100 | 5.69 |
| 12:24 ET | 1311 | 5.65 |
| 12:26 ET | 100 | 5.62 |
| 12:30 ET | 100 | 5.63 |
| 12:44 ET | 100 | 5.62 |
| 12:46 ET | 200 | 5.62 |
| 12:57 ET | 100 | 5.62 |
| 01:00 ET | 100 | 5.64 |
| 01:02 ET | 100 | 5.66 |
| 01:13 ET | 200 | 5.73 |
| 01:15 ET | 200 | 5.73 |
| 01:18 ET | 600 | 5.76 |
| 01:20 ET | 1014 | 5.71 |
| 01:26 ET | 273 | 5.675 |
| 01:36 ET | 100 | 5.71 |
| 01:45 ET | 100 | 5.75 |
| 01:47 ET | 300 | 5.7 |
| 02:27 ET | 100 | 5.68 |
| 02:32 ET | 300 | 5.71 |
| 02:34 ET | 400 | 5.7 |
| 02:50 ET | 100 | 5.705 |
| 02:54 ET | 300 | 5.69 |
| 03:06 ET | 300 | 5.67 |
| 03:12 ET | 600 | 5.69 |
| 03:17 ET | 100 | 5.7 |
| 03:21 ET | 100 | 5.71 |
| 03:24 ET | 279 | 5.7058 |
| 03:32 ET | 140 | 5.72 |
| 03:35 ET | 1359 | 5.6974 |
| 03:37 ET | 100 | 5.69 |
| 03:42 ET | 103 | 5.695 |
| 03:46 ET | 314 | 5.69 |
| 03:48 ET | 390 | 5.7 |
| 03:50 ET | 400 | 5.67 |
| 03:53 ET | 9847 | 5.635 |
| 03:55 ET | 200 | 5.65 |
| 04:00 ET | 13725 | 5.62 |
Nov 13, 2024
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 7, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Design Therapeutics Inc | 318.2M | -6.6x | --- |
Kodiak Sciences Inc | 325.7M | -1.8x | --- |
Jasper Therapeutics Inc | 330.8M | -4.8x | --- |
Lexicon Pharmaceuticals Inc | 312.1M | -1.1x | --- |
Compass Pathways PLC | 301.7M | -2.1x | --- |
Neurogene Inc | 301.6M | -5.0x | --- |
Company Information
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Contact Information
- Headquarters
- 6005 Hidden Valley Road, Suite 110CARLSBAD, CA, United States 92011
- Phone
- 858-293-4900
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
- Pratik Shah
- Chief Operating Officer
- Sean Jeffries
- Chief Medical Officer
- Jae Kim
- Lead Independent Director
- Simeon George
- Independent Director
- Heather Berger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $318.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 56.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.84 |
EPS | $-0.85 |
Book Value | $4.92 |
P/E Ratio | -6.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
